OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Deferred Income Tax
OSE Immunotherapeutics SA
Deferred Income Tax Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Deferred Income Tax | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Deferred Income Tax
€1.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Deferred Income Tax
€4.2m
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Deferred Income Tax
€171k
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Deferred Income Tax
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Deferred Income Tax
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Deferred Income Tax
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Deferred Income Tax?
Deferred Income Tax
1.2m
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Deferred Income Tax amounts to 1.2m EUR.
What is OSE Immunotherapeutics SA's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 5Y
-25%
Over the last year, the Deferred Income Tax growth was -10%. The average annual Deferred Income Tax growth rates for OSE Immunotherapeutics SA have been -12% over the past three years , -25% over the past five years .
You don't have any saved screeners yet